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INTRODUCTION
Background
The development of drug-resistant (DR) tuberculosis (TB) has become an increasing 
concern over the past few decades as the result of numerous factors, including widespread 
inappropriate or ineffectual use of antimicrobials to treat TB in the absence of drug-
susceptibility testing (DST), lack of adequate uptake of systematic approaches to the 
treatment of drug-susceptible (DS) TB and DR-TB, introduction of human 
immunodeficiency virus (HIV) into areas with preexisting DR-TB, provider error, poor 
adherence to treatment, lack of availability of effective drugs, and transmission of DR 
strains.1 The World Health Organization (WHO) has estimated that annually there are over 
half a million new cases of rifampicin-resistant (RR) and multidrug-resistant (MDR) TB; 
that is, disease caused by Mycobacterium tuberculosis with resistance to isoniazid and 
rifampin. Globally, 156,000 persons with MDR-TB or RR-TB began treatment in 2018, but 
the latest data show that only 56% completed treatment successfully.2 Such poor treatment 
completion rates are the result of treatment for a longer duration with second-line anti-TB 
drugs (SLDs), which are less effective and have greater toxicity than the 4 drugs most 
commonly used to treat DS-TB. However, treatment performance has been shown to be 
much better when regimens are designed carefully and ensure good retention, under both 
trial and programmatic conditions.3,4
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Definitions
There are many forms of DR-TB (Box 1). Definitions for extensively DR (XDR) TB and 
pre–XDR-TB need to be modified as all-oral regimens become standard of care.
Guidelines Development
The treatment and management of DR-TB has evolved significantly in the past decade with 
the advent of rapid molecular diagnostic tests, new and repurposed drugs, results based on 
individual patient data meta-analysis (IPD-MA),5–12 and a strategy to decentralize patient 
care in line with a patient-centered approach, including in high burden settings.13 The WHO 
has recently published an evidence-based update to its MDR-TB treatment guidelines,14 
introducing new regimens, enhanced monitoring strategies, and a feasible implementation 
plan, based on an IPD-MA of data from recently completed phase III trials of delamanid and 
a shorter MDR-TB regimen; an IPD-MA with more than 13,100 records from patients 
treated with longer MDR-TB regimens in 40 countries; another IPD-MA with more than 
2600 records from patients treated with the 9-month to 12-month shorter MDR-TB regimens 
from 15 countries; and pharmacokinetic and safety data from trials of bedaquiline and 
delamanid in patients less than or equal to 18 years old.14 These guidelines are intended to 
be applicable in low-resource countries. The American Thoracic Society (ATS), the Centers 
for Disease Control and Prevention (CDC), the European Respiratory Society (ERS), and the 
Infectious Disease Society of America (IDSA) are also collaborating to develop guidelines 
for low-incidence, high-resource countries, which they will publish in 2019, using published 
IPD-MA data from more than 12,000 patients treated with MDR-TB regimens from 25 
countries in 50 studies.8 At the time of the writing of this article, those guidelines have not 
been finalized, but will be based principally on a published IPD-MA8 and will be intended 
for settings in which mycobacterial cultures, phenotypic and molecular DST, and 
radiographic resources are readily available.
New Recommendations from the World Health Organization (2019)
The new WHO recommendations are a departure from previous approaches to treat MDR-
TB/RR-TB in several regards:
• Injectables are no longer considered priority medicines when designing longer 
MDR-TB regimens. Kanamycin and capreomycin are no longer recommended.
• Oral regimens are preferred for most patients.
• Fluoroquinolones (levofloxacin or moxifloxacin), bedaquiline, and linezolid are 
strongly recommended for all longer regimens (unless contraindicated), with 
other medicines ranked by a relative balance of benefits to harms.
• Most regimens should include at least 4 drugs that are likely to be effective in the 
first 6 months, and 3 drugs thereafter.
• The total duration of longer MDR-TB regimens should be 18 to 20 months, 
modified depending on patient response.
• A standardized, shorter MDR-TB regimen may be offered to eligible patients 
who agree to a briefer treatment (9–12 months) if they are cognizant that this 
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may be less effective than an individualized longer regimen and of the 
inconvenience/risks associated with the daily injectable agent needed for 4 to 6 
months.
• It is strongly recommended that MDR-TB regimens should be monitored with 
cultures rather than merely with sputum microscopy, and it is preferred that 
cultures are performed monthly to diagnose treatment failure, relapse, or 
unidentified/acquired drug resistance in a timely fashion.
• Bedaquiline may be given to children greater than or equal to 6 years old and 
delamanid to those greater than or equal to 3 years old.
• Regimens that vary substantially from the recommended composition and 
duration can be explored under operational research conditions.
• Patient-centered support for medication adherence (including the use of digital 
technologies where feasible) and active TB drug-safety monitoring and 
management (aDSM) are essential for anyone starting an MDR-TB regimen.
Key Principles/Best Practices
Several best-practices statements can readily be derived for diagnosing, treating, monitoring, 
and providing case management for DR-TB, based on expert opinion and on the IPD-MAs 
that have served as the basis for development of the 2019 WHO guidelines14:
• Treatment should follow evidence-based up-to-date guidelines of WHO or of 
other organizations with similar levels of expertise.
• Diagnosis, treatment, and management strategies differ depending on the 
epidemiology of TB, programmatic resources, and characteristics of different 
patient populations.
• Treatment and management of DR-TB or cases in which drug intolerance may 
complicate care should be done in consultation with an expert in the management 
of these complex cases.
• Quality-assured laboratory testing, including culture and DST, should be 
available for optimal patient care.
• Choice of drugs should be informed by quality-assured laboratory testing, 
including culture and DST, with avoidance of drugs to which there is 
documented resistance (individualized treatment).
• If possible, testing for rapid detection for molecular evidence of drug resistance 
in conjunction with growth-based DST should be performed when DR-TB is 
suspected, whether such suspicion has an epidemiologic or clinical basis.
• In using a longer treatment regimen, 5 drugs may be used rather than 4 drugs for 
the first 6 months of treatment (when using bedaquiline or in the initiation phase 
if an injectable agent is used) and 4 drugs rather than 3 drugs after 6 months (or 
during the continuation phase if an injectable agent is used) if it is deemed 
medically necessary and if resources allow.
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• Treatment choice and duration should be determined in conjunction with the 
strength of the drugs used for treatment, extent and severity of disease, and the 
treatment response as shown bacteriologically, clinically, and radiographically. 
Where possible, monthly cultures should be obtained during treatment. Weight 
should be monitored monthly.
• Never add a single drug to a failing regimen (as manifested by persistent culture 
positivity, or clinical or radiographic deterioration).
• If a shorter MDR-TB regimen (9–12 months) is to be implemented, it should be 
in countries where a longer regimen (18–20 months) is not feasible.
• An uninterrupted supply of quality-assured drugs should be ensured.
• Active pharmacovigilance for serious adverse events (SAEs) and passive 
pharmacovigilance for adverse drug reactions (ADRs) are crucial. At each 
patient contact while on treatment, patients should be asked about possible 
ADRs, with attention to identification of toxicities or other evidence of issues in 
tolerability of the anti-TB drugs and any ADRs or SAEs should be reported 
immediately. All ADRs merit investigation and early action to limit harms. 
Collection of detailed data on SAEs may help patients and programs to improve 
performance.
• Treatment adherence should be ensured through directly observed therapy (DOT) 
or supported using information communication technology (ICT)–based 
adherence strategies.15
• A patient-centered approach with case management strategies (incentives and 
enablers) should be used, with attention to the social, cultural, and environmental 
aspects of care, treatment of comorbid conditions such as HIV, malnutrition, 
diabetes, smoking and alcoholism, and palliative care if needed.
• Posttreatment monitoring should be performed at regular intervals (eg, every 6 
months) for 1 to 2 years to evaluate for relapse or recurrence.
• DR-TB contacts should be evaluated to exclude TB disease and offered treatment 
of latent TB infection (LTBI) tailored to the susceptibility pattern of the source-
case isolates whenever possible.
For use of rapid molecular diagnostic tests, see Michelle K. Haas and Robert W. Belknap’s 
article, “Diagnostic Tests for Latent Tuberculosis Infection,” in this issue. For treatment of 
HIV, see the article in this issue on treatment of HIV.
CLASSIFICATION OF DRUGS
In 2018, WHO revised the classification of anti-TB drugs based on a recent IPD-MA 
analyzing the relative risk of treatment failure or relapse versus treatment success, death 
versus treatment success, and the SAEs for each individual drug.5,8,10 This classification 
(Table 1) is used to devise the longer-treatment WHO regimen (lasting for a total treatment 
duration of 20 months), because the standardized shorter treatment regimen (lasting 12 
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months or less) is composed of a fixed regimen of drugs that cannot be substituted unless 
done in a research mode.14
The key recommendations in the new WHO reclassification scheme for anti-TB drugs are as 
follows:
• Fluoroquinolones (levofloxacin and moxifloxacin), bedaquiline, and linezolid 
(group A) were considered highly effective and are strongly recommended to be 
included in an MDR-TB regimen unless contraindicated.
• Clofazimine and either cycloserine or terizidone (group B) are conditionally 
recommended as second-choice drugs.
• Drugs are in group C ranked by the balance of benefit to harm and can be 
considered when group A or B drugs are not available to build an adequate 
multidrug regimen.
• Injectable agents, amikacin and streptomycin, have been downgraded to group C 
and are not included if an adequate regimen can be built without them. 
Kanamycin and capreomycin are no longer recommended for use.
• Gatifloxacin and thioacetazone are either not available or not being used, and 
therefore are not included in the recommendations.
• High-dose isoniazid may have a role when there is confirmed isoniazid 
susceptibility or when only an inhA mutation is detected in longer MDR 
regimens and is a standard drug in the shorter MDR regimen.
• Clavulanic acid (only available in the combination amoxicillin-clavulanic acid 
form [Augmentin]) should only be given with a carbapenem (eg, meropenem) 
and should not be individually counted as an anti-TB drug.
• There is no recommendation for the use of 4-thioureidoiminomethyl pyridinium 
perchlorat interferon-gamma, or sutezolid and no evidence that they increase 
likelihood of cure.
• Bedaquiline can be given to children greater than or equal to 6 years of age.
• Delamanid can be given to children greater than or equal to 3 years of age.
• There is no recommendation for giving bedaquiline and delamanid together.
• Bedaquiline and delamanid should be given for 6 months and, if extended, would 
be considered off-label use.
• Pyrazinamide should only be counted in the regimen if susceptibility is shown.
• Amikacin and streptomycin should only be used if susceptibility is confirmed 
(phenotypic conformation for streptomycin) and if high-quality audiology 
monitoring is available.
These results reflect analyses from 3 IPD-MA cohorts.14 ATS/CDC/ERS/IDSA guidelines 
are being developed using data from a single IPD-MA8 with a patient cohort (overlapping, 
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but not identical) similar to that of one of the cohorts used in developing the WHO 
guidelines.14
The results of the IPD-MA used in developing the ATS/CDC/ERS/IDSA guidelines differed 
from that used in developing the WHO treatment guidelines in the following ways:
1. Amikacin and streptomycin showed better effectiveness if susceptibility was 
confirmed.
2. Treatment outcomes were significantly worse for patients treated with drugs for 
which there was documented resistance.
3. Fewer data were available on bedaquiline, resulting in a less pronounced effect of 
bedaquiline on treatment outcome.
In turn, these findings and other differences, such as the availability of rapid molecular 
testing for the detection of drug resistance, phenotypic DST for additional SLD, and 
therapeutic drug monitoring, may lead to some differences in recommendations in treatment 
approaches for low-incidence settings.
BUILDING A TREATMENT REGIMEN
MDR-TB/XDR-TB should always be treated with a multidrug regimen consisting of drugs 
to which the patient’s isolate is susceptible, excluding all drugs to which the isolate shows 
resistance. If DST is not available or an empiric DR-TB regimen must be started before DST 
results are available, the regimen should consist of drugs that are highly likely to be 
susceptible or effective, based on previous treatment history, pattern of resistance of the 
presumed source case, potential for cross-resistance with drugs for which DST is available 
(see Table 9), and patterns of resistance found from national or regional drug-resistance 
surveys (DRSs) that tend to indicate the local effectiveness of different drugs. In addition, 
when only rapid molecular testing for rifampin resistance is available (eg, Xpert MTB/RIF 
assay, Cepheid, Sunnyvale, CA),16 RR-TB should be treated as if it were MDR-TB.14 
However, in the United States and other low-prevalence countries, false resistance is 
common with Xpert MTB/RIF assay (low PPV); in such settings, sequencing is 
recommended to confirm rpoB mutation and assess for potential mutations conferring 
isoniazid resistance to diagnose MDR-TB.
When treated with an inadequate treatment regimen, DR mutant strains of M tuberculosis in 
the bacterial population are favored, leading to treatment failure, relapse, further acquired 
drug resistance, and potentially death. According to the new 2019 updated WHO DR-TB 
guidelines, a longer MDR-TB regimen can be used for MDR/RR-TB, lasts for at least 18 
months, and can be either standardized or individualized. A shorter MDR-TB regimen can 
be used for MDR/RR-TB, is largely standardized, and is given for 9 to 12 months (Fig. 1 
shows the choice of longer vs shorter regimens).
Longer Treatment Regimen
According to the new WHO guidelines, a longer treatment regimen (preferably all oral) 
should be designed using the following principles.
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Recommendations
• Recommendation 1: if an injectable agent is used, the duration of the intensive 
phase should be 6 to 7 months (Box 2).
• Recommendation 2: a total duration of 18 to 20 months is recommended.
• Recommendation 3: treatment duration of 15 to 17 months after culture 
conversion is recommended.
• Other recommendations:
– All 3 group A drugs and at least 1 group B drug should be included for 
a total of at least 4 drugs given for 6 months until bedaquiline is 
stopped and a total of at least 3 drugs for the remainder of the treatment 
duration (Table 2).
– If 1 or 2 group A drugs cannot be included, the remaining group A 
drugs, both group B drugs and group C drugs (if needed) should be 
added (in order of ranking) to achieve at least 4 drugs at start of 
treatment.
– If 1 or 2 group A drugs cannot be included and 1 or both group B drugs 
cannot be included, group C drugs should be added (in order of 
ranking) to achieve at least 4 drugs at start of treatment.
– If 2 agents are likely to be stopped before the end of treatment (eg, 
bedaquiline at 6 months and linezolid because of toxicity), 5 agents 
may be given at start of treatment to ensure that 3 agents can be given 
for the duration of treatment.
– Duration of treatment depends on the drugs used in the regimen and 
may be decreased or extended depending on the patient’s response to 
treatment.
Implementation considerations
• When there is additional resistance to simple MDR-TB, a longer regimen may be 
preferable to a shorter regimen.
• An all-oral regimen should be the preferred choice for most patients.
• Ideally, all drugs used in a regimen should have confirmed susceptibility.
• Ideally, all patients with RR-TB should have DST to isoniazid to exclude non-
MDR RR-TB or polydrug-resistant (PDR) TB.
• Ideally, all patients with MDR-TB should have DST to a fluoroquinolone, and, if 
an injectable is to be used, DST to second-line injectable (SLI) agents.
• Ideally, DST for bedaquiline, delamanid, linezolid, and pyrazinamide should be 
performed.
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• Ideally, patients should have molecular testing for inhA and katG mutations to 
look for ethionamide/low-dose isoniazid resistance and high-dose isoniazid 
resistance respectively.
• DST to other SLDs should be obtained where available and quality assured.
• When DST is not available, selection of drugs should be based on DST pattern of 
presumed source case, treatment history, cross-resistance between drugs, and 
surveillance data from national or regional DRS.
• Although the GenoType MTBDRs/ (Hain Life-science GmbH, Nehren, 
Germany) assay, the only rapid commercial test for detection of resistance to the 
principal SLDs, may correlate well with phenotypic resistance to ofloxacin and 
levofloxacin, moxifloxacin resistance is best confirmed through phenotypic 
testing.
• When there is uncertainty about the efficacy of a particular drug, it can be 
included as part of the regimen, but not included numerically as one of the 
effective drugs.
• Five drugs rather than 4 may be started with initial treatment if:
– Two of the 4 drugs are likely to be stopped before completion of 
treatment.
– There is a question as to the efficacy of 1 or more drugs because of lack 
of quality DST and high level of resistance to that drug, or 1 of the 
drugs in the regimen shows cross-resistance with another drug for 
which there is known or suspected resistance.
– The regimen is unlikely to be successful based on a factor such as the 
extent of resistance.
– All 3 group A drugs are not used.
Clinical strategy to build an individualized treatment regimen
Principles
• Build a regimen using greater than or equal to 4 drugs to which the isolate is 
susceptible (or has low likelihood of resistance), preferably with drugs that have 
not been used to treat the patient previously.
• Choice of drugs depends on DST, previous treatment history, the pattern of 
resistance of the presumed source case, patterns of resistance found from 
national or regional DRS capacity to appropriately monitor for significant 
adverse effects, patient comorbidities and preferences/values (choices therefore 
subject to program and patient safety limitations).
• In children with TB disease who are contacts of infectious MDR-TB source 
cases, the source case’s isolate DST result should be used if no isolate is 
obtained from the child.
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• TB expert medical consultation is recommended.
Shorter Regimen
Per WHO guidelines, if a shorter treatment regimen is implemented, it should be designed 
using the following principles.
Recommendations
• The shorter regimen consists of 4 to 6 months of moxifloxacin, amikacin, 
ethionamide, clofazimine, high-dose isoniazid, pyrazinamide, and ethambutol 
(depending on smear conversion at 4 months), followed by 5 months of 
moxifloxacin, clofazimine, pyrazinamide, and ethambutol.
• The shorter regimen may be considered for patients who desire a shorter duration 
of treatment despite the use of an injectable agent and who do not have the 
exclusion criteria noted in Box 3.
• Patients should only be started on the shorter regimen if they have confirmed 
susceptibility to fluoroquinolones and SLI agents by molecular or phenotypic 
DST.
• Ideally, patients should have molecular testing for inhA and katG mutations to 
look for ethionamide/low-dose isoniazid resistance and high-dose isoniazid 
resistance respectively; if both mutations are present, a longer MDR-TB regimen 
should be considered.
• Ideally, patients should also have phenotypic DST to pyrazinamide before 
starting the shorter regimen, but this should not preclude the use of the regimen if 
needed.
Implementation considerations
• Patients eligible for shorter regimens may still opt for a longer regimen if they 
want to avoid SLI agents on the understanding that they need a much more 
protracted course of medication.
• Kanamycin should be replaced by amikacin.
• If any drug in the regimen or essential monitoring (especially audiometry) are 
unavailable, a longer regimen should be used.
• If an all-oral shorter regimen (eg, replacing kanamycin with bedaquiline) is 
implemented, this should be done in an operational research mode because there 
are no data on an all-oral shorter regimen.
• If DRS results show high levels of resistance to any drug in the shorter regimen, 
especially ethionamide, fluoroquinolone, or pyrazinamide, a longer regimen 
should be considered.
• The shorter regimen should be given by DOT or an information and ICT-based 
adherence method.18
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Rifampin-Resistant Tuberculosis (Isoniazid Susceptible)
In cases with rifampin resistance in which susceptibility to isoniazid is confirmed:
Recommendations
• Expert opinion customarily holds that a longer or shorter MDR-TB regimen may 
be used with the addition of high-dose isoniazid if there is no DST for 
ethambutol and/or pyrazinamide and if there is a high level of baseline resistance 
to either drug based on surveillance data.
• If DST to all first-line drugs and fluoroquinolones is available, please refer to 
Table 3 for a DST-driven treatment regimen.
Implementation considerations
• The regimen used for RR-TB depends on the availability to perform molecular or 
phenotypic DST to the other first-line drugs and fluoroquinolones, and the 
availability of quality-assured drugs in country.
• Wherever possible, molecular or phenotypic DST should be performed for 
isoniazid to confirm lack of MDR-TB.
Isoniazid-Resistant Tuberculosis (Rifampin Susceptible)
In cases with isoniazid-resistant TB in which susceptibility to rifampin is confirmed:
Recommendations
• Treatment with rifampin, ethambutol, pyrazinamide, and levofloxacin 
recommended for a duration of 6 months.14
• The 4-drug HREZ fixed-dose combination (FDC) with isoniazid, rifampin, 
ethambutol, and pyrazinamide may be used (because there is no approved 
rifampin-ethambutol-pyrazinamide FDC available) to limit the need for using 
single drugs.
• Drug susceptibility to fluoroquinolones should preferably be confirmed ahead of 
start of treatment.
• It is generally not recommended to add streptomycin or other injectable agents to 
the treatment regimen.
Implementation considerations
• If isoniazid resistance is confirmed before start of treatment, follow the 
recommendations outlined earlier.
• If isoniazid resistance is suspected (based on source-case isolate), start isoniazid, 
rifampin, ethambutol, and pyrazinamide empirically, and add a fluoroquinolone 
only after RR-TB has been reliably excluded; if isoniazid susceptibility is 
confirmed, change to standard 4-drug regimen for DS-TB.
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• If isoniazid resistance is confirmed after treatment start (either because of 
unidentified resistance at treatment start or acquired resistance), exclude rifampin 
resistance immediately through molecular testing and, if rifampin susceptible, 
change regimen to rifampin, ethambutol, pyrazinamide, and a fluoroquinolone 
for 6 months; if rifampin resistance is found, start treatment of MDR-TB.
• If isoniazid resistance is diagnosed 4 to 5 months after treatment start, treatment 
should be based on patient’s clinical, bacteriologic, and radiographic response 
and further DST results.
• Ideally, fluoroquinolone resistance should be excluded before starting this 
regimen using a line probe assay to detect resistance to SLDs, especially in 
countries with high levels of fluoroquinolone resistance based on DRS.
• Levofloxacin is the recommended fluoroquinolone based on its safety profile and 
fewer drug-drug interactions, particularly with antiretrovirals.
• Moxifloxacin should be considered if only levofloxacin or low-level 
moxifloxacin resistance is confirmed (moxifloxacin less than or equal to 1.0 
μg/mL Lowenstein-Jensen; less than or equal to 0.5 μg/mL Middlebrook 
7H10/7H11; ≤0.25 μg/mL BACTEC MGIT).19
• A fluoroquinolone should be used unless any of the following are present:
– Resistance to rifampin cannot be excluded (ie, unknown susceptibility 
to rifampin; indeterminate/error results on GeneXpert MTB/RIF).
– Known or suspected resistance to levofloxacin; moxifloxacin may be 
considered (discussed earlier).
– Known intolerance to fluoroquinolones.
– Known or suspected risk for prolonged QT interval, or high risk for or 
known aortic aneurysm.20
– In pregnancy or during breastfeeding (not an absolute contraindication).
• If a fluoroquinolone cannot be used, isoniazid, rifampin, ethambutol, and 
pyrazinamide can be given for 6 months.
• The duration of treatment can be extended based on delayed clinical, 
bacteriologic, and radiographic response.
• The addition of isoniazid is based on FDC use and there are no data on added 
efficacy; if there are side effects attributed to isoniazid, single drugs (rifampin, 
ethambutol, pyrazinamide, fluoroquinolone) should be used.
• Streptomycin or other injectable agents can be added to the regimen in certain 
exceptional circumstances (see Table 3).
• If DST to all first-line drugs and fluoroquinolones is available, please refer to 
Table 3.
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Polydrug Resistance (Isoniazid Susceptible)
Recommendations—For patients with PDR-TB for whom DST to all first-line drugs and 
fluoroquinolones is available, treatment decisions must be guided largely by expert opinion, 
rather than through recommendations developed through the GRADE (Grading of 
Recommendations Assessment, Development and Evaluation) methodology21,22 because of 
the paucity of available data to inform such a process. Table 3 shows adapted and updated 
recommendations for individualized treatment (primarily based on expert opinion) from the 
Curry International Tuberculosis Center DR-TB Survival Guide.17
Implementation considerations
• These recommendations are primarily applicable when DST is available for all 
first-line drugs and fluoroquinolones.
• As with MDR-TB, for RR-TB (isoniazid susceptible) with or without additional 
resistance, clinicians and patients may prefer an all-oral MDR-TB regimen, 
incorporating bedaquiline, rather than an injectable-containing regimen.
• In countries or settings where DST to ethambutol and pyrazinamide are not 
available:
– Treat RR-TB as if it were MDR-TB, and
– Treat any isoniazid-resistant TB per WHO guidelines as set out in 
relation to treatment of isoniazid-resistant TB.
TREATMENT IN SPECIAL SITUATIONS
Extrapulmonary Tuberculosis
• The longer MDR-TB regimen may be given in extrapulmonary TB; TB 
meningitis should be treated with a regimen of drugs that achieve effective drug 
levels in the central nervous system (CNS) (Table 4) and should be directed by 
DST.
• In culture-negative extrapulmonary TB or when culture conversion cannot be 
shown because of inability to obtain a specimen, a total duration of treatment of 
18 to 20 months is recommended; if an injectable agent is used, it should be 
given for 6 to 7 months based on clinical response.
• The shorter regimen should be avoided in patents with disseminated or CNS 
disease and in persons living with HIV.
• There is no difference in other regimens for other forms of DR-TB specific to 
extrapulmonary TB.
• Monthly cultures may not be possible in extrapulmonary TB; therefore, 
monitoring for response to therapy may be based on clinical and/or radiographic 
response.
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Pregnancy
There is a paucity of data on the treatment of DR-TB in pregnancy. Untreated MDR-TB 
during pregnancy can be associated with adverse maternal and fetal outcomes.
• The benefits of treatment of DR-TB to mother, child, and the community 
outweigh the harms.
• An all-oral individualized longer regimen is preferable in order to avoid drugs 
that may be teratogenic (Table 5).
• The shorter regimen should be avoided in pregnancy.
• Patients on treatment of DR-TB should be counseled to avoid pregnancy and a 
birth control method should be recommended; oral contraceptives should be 
avoided as the method for birth control if rifampin is to be used in the regimen, 
because of drug-drug interactions rendering oral contraceptive pills less effective.
Children
There is a paucity of data on the treatment of DR-TB in children, so many of the 
recommendations made for adults have been extrapolated to children.10
• The longer oral MDR-TB regimen is recommended in children. Injectable agents 
are used only when other drugs cannot be used because of resistance or toxicity.
• Injectable agents are avoided whenever possible because of the adverse side 
effect of hearing loss, painful injections, and because children often have 
paucibacillary disease.
• Given that children are often culture negative, a total treatment duration of 18 to 
20 months should be given with a low threshold to decrease the duration in the 
case of children with less extensive or severe disease.
• A shorter MDR-TB regimen may be given in children, although avoiding the 
injectable agent may be factored into the decision between the longer and the 
shorter regimens.
• Gastric aspirates should be obtained for diagnosis and follow-up in young 
children who cannot produce sputa.
• Child-friendly formulations should be given whenever possible, and breaking of 
adult-sized pills should be minimized because the efficacy of drugs may be 
affected by altering the physical properties of the drug.
Comorbid Conditions
The treatment of DR-TB in the setting of comorbid conditions such as diabetes mellitus, 
tobacco use, alcoholism, and drug use is similar to the treatment of DS-TB in these settings 
except for the need for dose adjustment of SLDs in the case of renal or hepatic insufficiency. 
An expert in the management of DR-TB should be consulted in these circumstances.
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TREATMENT OF DRUG-RESISTANT TUBERCULOSIS CONTACTS
The treatment of DR-TB contacts seems to have some efficacy in preventing progression to 
TB disease.27–29 DR-TB contacts should be evaluated to exclude TB disease and offered 
treatment of LTBI tailored to the susceptibility pattern of the source-case isolates whenever 
possible. Table 6 shows the treatment patterns for appropriate drug choices in this setting.17
There are currently 3 ongoing randomized controlled trials evaluating the efficacy of treating 
contacts of persons with MDR-TB/XDR-TB.30,31 Close contacts to patients with DR-TB 
may be considered for prophylactic treatment using the principles set out in Box 4:
MONITORING AND EVALUATION
Response to Treatment
• Patients being treated for DR-TB should be closely monitored for treatment 
failure, acquired drug resistance, loss to follow-up, and potential ADRs.
• Patients should be followed at regular intervals clinically, radiographically (if 
pulmonary disease), and bacteriologically.
• Monthly cultures should be obtained throughout the treatment duration, and, if 
still positive at 3 to 4 months,14,32 or reverts to positive after conversion, DST 
should be obtained right away to exclude acquired resistance.
• When feasible, an end-of-treatment culture should be obtained to show and 
document treatment cure.
• Patients should be monitored posttreatment completion at regular intervals for 1 
to 2 years for relapse.
Adverse Drug Reaction Monitoring
One of the biggest obstacles to successful completion of treatment and cure is unrecognized/
unmanaged or mismanaged ADRs. Early detection and appropriate management of ADRs 
minimize treatment interruptions, loss to follow-up, and poor treatment outcomes such as 
treatment failure, relapse, and acquired drug resistance.
• Per WHO, TB programs need to have comprehensive pharmacovigilance 
programs in place with aDSM to ensure early detection, timely reporting, and 
appropriate management of ADRs and SAEs, as the standard of care for all 
patients on any MDR regimen.33
• Training and education of field staff is necessary for proper management of 
ADRs.
• A list of common ADRs and associated TB drugs is provided in Table 7.
• Routine monitoring for ADRs and SAEs should be performed while patient is on 
treatment (see Table 7; Table 8).
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• Note that intolerance to 1 drug in a drug class does not automatically imply 
intolerance to all drugs in the drug class (eg, rifabutin may be tolerated when 
rifampin is not).
ADDITIONAL CONSIDERATIONS
Selection of Drugs
The following principles apply when building a DR-TB treatment regimen:
• Cross-resistance: avoid using drugs that have known cross-resistance to other 
drugs to which the isolate shows resistance (eg, isoniazid and ethionamide) 
(Table 9).
• Avoid previously used drugs (based on history): avoid using drugs that the 
patient has taken for greater than or equal to 1 month previously unless DST 
shows the drug organism to be fully susceptible to the drug.
• Consider side effects: chose drugs that will not potentiate or worsen underlying 
illnesses or symptoms (eg, cycloserine if the patient has underlying mental 
illness).
• Drug-drug interactions: avoid drugs that have known interactions with other 
drugs that the patient is taking (eg, bedaquiline and efavirenz).
Administration of Medications
Adherence to the complete DR-TB treatment regimen for the full duration is crucial for 
relapse free cure. Minimizing treatment interruptions caused by ADRs/SAEs and loss to 
follow-up requires patient education, good case management, active pharmacovigilance, 
adherence strategies, and a patient-centered approach to care.
• Dose escalation: one of the measures that may minimize side effects such as 
nausea and vomiting is the dose escalation method when beginning DR-TB 
drugs such as ethionamide, para-aminosalicylic acid, and cycloserine (Fig. 2). 
Escalating the dose of drugs over a week allows the patient to get used to the 
drug and mitigate side effects.
• Adherence measures/patient-centered approach: a patient-centered approach 
considers the values and preferences of the patient during treatment. It is the 
approach that is likely to result in the most humane and effective treatment 
strategy to ensure cure and other good outcomes.13
– Ideally medication should be given once daily via DOT.
– Twice-daily dosing is generally discouraged because of the challenge 
posed for full adherence.
• Intermittent dosing is not advised except in the case of an injectable agent that 
can be decreased in frequency of dosing to twice or thrice weekly after sputum 
culture conversion has occurred, generally after 2 to 3 months of therapy, to 
minimize the potential for toxicity.
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• Intermittent dosing may be required with clofazimine in children (see online 
Table).35
• Palliative care: when there is no treatment option available because of extensive 
resistance and disease, the patient must receive palliative measures such as pain 
management and management of dyspnea to provide the most humane care 
possible. It is also necessary to follow infection control practices to minimize 
transmission of DR-TB to family members and the community.
THERAPEUTIC DRUG MONITORING
Therapeutic drug monitoring (TDM), or the measurement of serum levels of drugs, can be 
an important test to check for treatment adherence (confirming ingestion of TB drugs), for 
adequate dosing of TB drugs, and to maximize efficacy and minimize toxicity of TB drugs.
36
• A quality-assured laboratory is required for TDM.
• A pharmacology specialist is required for performing TDM and interpreting the 
results.
• TDM may be helpful in the following situations:
– For dosage of toxic drugs like amikacin, linezolid, cycloserine.
– In renal insufficiency, diabetes mellitus, HIV infection, and other 
comorbid conditions that may affect the absorption or excretion of 
drugs.
– For patients with evidence of treatment failure or relapse while on an 
appropriate treatment regimen.
– When patients have few effective drugs in the treatment regimen based 
on DST results.
– When drug-drug interactions are likely.
SURGERY
Patients with extensive resistance, extensive disease, or localized disease may benefit from 
surgical resection in addition to treatment37 with a DR-TB treatment regimen, especially 
when there is a high risk of relapse or treatment failure with chemotherapy alone.
• Patients should have preoperative evaluation to determine that they are good 
surgical candidates, to ensure that they will have adequate lung capacity after 
surgery, and to ensure that they are not at risk for pulmonary hypertension after 
surgery.
• Lobectomy or wedge resection is the procedure of choice.
• Surgery should be performed by a surgeon with expertise in TB surgery.
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• Proper infection control mechanisms should be in place during surgery 
(ultraviolet light, personal protective equipment).
• An appropriate treatment regimen should be given in conjunction with surgery, 
because surgery alone is not curative.
DRUG DOSAGES
In the recent updated WHO DR-TB guidelines, adult and pediatric drug dosages have been 
revised. The revised dosages may be found in online Table.35
WORLD HEALTH ORGANIZATION TREATMENT OUTCOMES
A recent publication from the Global TB Network38 suggests several proposed revisions to 
the current WHO definitions of TB treatment outcomes to address some of the recent 
changes in treatment regimens (eg, all-oral regimens) and evolution in programmatic 
definitions for treatment outcomes. Table 10 highlights current WHO treatment outcome 
definitions.14
RESEARCH PRIORITIES
Like numerous other pathogens, M tuberculosis complex has a remarkable ability to evolve 
and adapt to the presence of antimicrobials, developing virulence or resistance to commonly 
used drugs and rendering them ineffective. From programmatic and clinical perspectives, 
there are several areas in which research will continue to be needed for addressing drug 
resistance of TB. From a programmatic perspective, it is important that strategies are 
developed to improve appropriate antimicrobial use and ways of achieving adherence. From 
a clinical perspective, it is important that clinical trials are conducted to validate use of 
existing and new drugs and regimens and improve on the methods for conducting 
surveillance and monitoring of drug resistance. Over the past decade, the products of several 
comprehensive efforts to identify research priorities for TB have been published.39–41 These 
areas of research include:
• Randomized controlled trials, including new drugs and shorter all-oral regimens.
• Studies to include children, pregnant women, extrapulmonary disease, persons 
living with HIV, patients with other comorbid conditions.
• Pharmacokinetic studies to determine optimal dosing and safety of drugs.
• Documentation of ADRs and SAEs through programmatic pharmacovigilance.
• Shorter MDR-TB regimens and their use in subgroups such as children, pregnant 
women, and patients with extrapulmonary disease.
• Optimal duration of the longer MDR-TB regimen.
• Predictors and biomarkers of treatment failure and relapse.
• Studies on optimal methods to achieve patient adherence.
• Optimal duration of posttreatment monitoring for relapse.
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• Optimal regimen and duration of treatment of MDR-TB contacts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
APPENDIX 1:: RESOURCES FOR THE MANAGEMENT OF DRUG-
RESISTANT TUBERCULOSIS
1. Four regionally assigned CDC-supported TB Centers of Excellence (COEs), 
formerly known as Regional Training and Medical Consultation Centers. The TB 
COEs support domestic TB prevention and control efforts by increasing 
knowledge, skills, and abilities through communication, education, and training 
activities, and by improving evidence-based TB clinical practices and patient 
care through the provision of expert medical consultation (https://npin.cdc.gov/
featured-partner/tb-regional-training-and-medical-consultation-centers-
rtmccshttps://sntc.medicine.ufl.edu/rtmccproducts.aspx).
a. Curry International Tuberculosis Center, part of the University of 
California at San Francisco (https://www.currytbcenter.ucsf.edu/)
b. Global Tuberculosis Institute at Rutgers, the State University of New 
Jersey (http://globaltb.njms.rutgers.edu/)
c. Heartland National Tuberculosis Center in San Antonio, part of the 
University of Texas Health Science Center at Tyler (https://
www.heartlandntbc.org/)
d. Southeastern National Tuberculosis Center at the University of Florida 
in Gainesville, Florida (https://sntc.medicine.ufl.edu/home/index#/)
2. Curry International Tuberculosis Center Drug-Resistant TB Survival Guide 
https://www.currytbcenter.ucsf.edu/products/view/drug-resistant-tuberculosis-
survival-guide-clinicians-3rd-edition
3. European Respiratory Society Consultation service (http://www.waidid.org/site/
clinicalIntro)
4. CA State MDR-TB Consultation Service (https://www.cdph.ca.gov/
Programs/CID/DCDC/CDPH%20Document%20Library/TBCB-MDR-Fact-
Sheet.pdf)
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Box 1
Drug-resistant tuberculosis definitions
• Monodrug-resistant TB: TB caused by organisms that show resistance to a 
single anti-TB drug (eg, isoniazid, rifampin, ethambutol, or pyrazinamide).
• Isoniazid-resistant TB: TB caused by organisms that show resistance to 
isoniazid (rifampin susceptible).
• Rifampin-resistant TB (RR-TB): TB caused by organisms that show 
resistance to rifampin, but may be susceptible to isoniazid, or resistant to 
isoniazid (ie, MDR-TB), or resistant to other first-line TB medicines 
(polydrug resistant) or second-line TB medicines (eg, extensively drug-
resistant TB [XDR-TB]).
• Polydrug-resistant TB (PDR-TB): TB caused by organisms that show 
resistance to more than 1 anti-TB drug, but not including both isoniazid and 
rifampin.
• MDR-TB: TB caused by organisms that show resistance to at least isoniazid 
and rifampin.
• Preextensively drug-resistant TB (pre–XDR-TB): TB caused by organisms 
that show multidrug resistance, and resistance to any fluoroquinolone or a 
second-line injectable (SLI) agent (ie, amikacin, kanamycin, or capreomycin).
• Extensively DR TB (XDR-TB): TB caused by or ganisms that show 
multidrug resistance, and resistance to any fluoroquinolone and at least 1 of 
the SLI agents.
• Primary or newly diagnosed DR-TB: DR-TB in a person who has previously 
received no or less than 1 month of anti-TB treatment (ATT).
• Acquired or previously treated DR-TB: TB in a person who has previously 
received at least 1 month of ATT.
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Box 2
Duration of treatment of longer multidrug-resistant tuberculosis regimen 
(refer to recommendations 1–3, given earlier, in building a treatment 
regimen)
• When an injectable agenta is used, all 3 recommendations apply for duration 
of treatment.
• When an all-oral regimen is used, recommendations 2 and 3 apply for 
duration of treatment.
• With extrapulmonary disease, only recommendation 3 applies for the duration 
of treatment.
• Changes to the recommended duration of treatment should be tailored to the 
patient’s bacteriologic, clinical, and radiographic response.
a
 Injectable agent here does not refer to meropenem and imipenem-cilastatin; this term is 
used to refer to amikacin or streptomycin (kanamycin and capreomycin are no longer 
recommended).
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Box 3
Exclusion criteria for the shorter regimen
• Resistance to or suspected ineffectiveness to a medicine in the shorter MDR-
TB regimen (except isoniazid resistance)
• Exposure to 1 or more second-line medicines in the regimen for greater than 1 
month (unless susceptibility to these second-line medicines is confirmed)
• Intolerance to any medicine in the shorter MDR-TB regimen or risk of 
toxicity from a medicine in the shorter regimen (eg, drug-drug interactions)
• Pregnancy
• Disseminated, meningeal, or central nervous system TB
• Any extrapulmonary disease in patients with HIV
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Box 4
Principles for the treatment of drug-resistant tuberculosis contacts
• Contacts to DR-TB should have a positive test for LTBI and have TB disease 
excluded before receiving treatment of presumed MDR LTBI.
• Treatment with 1 to 2 drugs to which the presumed source-case isolate shows 
susceptibility may be given for a period of 6 to 12 months (see Table 6).
• For isoniazid-resistant or PDR-TB (rifampin susceptible), rifampin may be 
given for a period of 4 months.
• For RR-TB or PDR-TB (isoniazid susceptible), isoniazid may be given for 6 
to 9 months.
• For MDR-TB, 6 to 12 months of treatment can be given with a 
fluoroquinolone alone or with a second drug, based on source-case isolate 
DST.
• When 2 drugs are used, based on evidence of increased toxicity, ADR, and 
discontinuations, expert opinion is that pyrazinamide should not be routinely 
used as the second drug.
• In lieu of fluoroquinolone-based treatment, there are few data for the use of 
other second-line medications and, because of toxicity, they are not 
recommended by experts.
• For contacts to fluoroquinolone-resistant, pre–XDR-TB, pyrazinamide and 
ethambutol may be an effective option, if source-case isolate DST shows 
susceptibility to these drugs.
• For contacts to fluoroquinolone-resistant, pre–XDR-TB with resistance to all 
first-line drugs, consider ethionamide/p-aminosalicylic acid or the newer 
drugs bedaquiline or delamanid. Studies are underway with delamanid.
• In children, TB drugs are generally better tolerated, and levofloxacin is 
preferred because of the availability of an oral suspension formulation.
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KEY POINTS
• A patient-centered approach with case management strategies should be used 
in the care of drug-resistant (DR) tuberculosis (TB) with attention to patient 
preferences; social, cultural, and environmental aspects of care; comorbid 
conditions, adherence strategies, patient monitoring for clinical response and 
safety, and the need for palliative care.
• There are 2 World Health Organization–recommended treatment options for 
multidrug-resistant (MDR) or extensively DR (XDR) TB that can be decided 
on based on extent of resistance, availability of drug susceptibility testing 
(DST) results, and patient preference:
a. If the clinician and patient opt for an individualized, longer 
treatment regimen, MDR-TB/XDR-TB should be treated with at 
least 4 drugs for the first 6 months, followed by 3 drugs for a total 
duration of 18 to 20 months depending on extent and severity of 
disease; drug history; and clinical, bacteriologic, and radiographic 
response.
b. If none of the exclusion criteria for the standardized shorter regimen 
are met and the clinician and patient opt for this regimen, MDR-TB/
XDR-TB should be treated for 9 to 12 months with the standardized 
medications and duration of treatment specified in the shorter 
regimen.
• The choice of drugs for the treatment of DR-TB should be guided by known 
effectiveness of given drugs, propensity for adverse drug reactions/drug-drug 
interactions, and DST, excluding all drugs to which the isolate shows 
resistance. If DST is only partially available or not available, or if an empiric 
DR-TB regimen must be started before DST results are available, the regimen 
should consist of drugs that are highly likely to be susceptible, based on 
previous treatment history, pattern of resistance of the presumed source case, 
and patterns of resistance found from national or regional drug-resistance 
surveys.
• An all-oral treatment regimen including new and repurposed drugs is the 
preferable strategy for most patients; injectable agents should be avoided 
whenever possible, especially in children.
• Expert consultation from a recognized DR-TB expert should be sought 
whenever possible in the treatment of patients with MDR-TB/XDR-TB or 
patients in whom issues of drug resistance or drug intolerance may 
complicate care.
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Fig. 1. 
Criteria to decide when the shorter MDR-TB regimen may be offered.14 a Strains from 
patients with MDR-TB/RR-TB should ideally be tested for resistance to fluoroquinolones 
and other regimen components regardless of the type of MDR-TB treatment regimen 
offered. (From the WHO treatment guidelines for DR-TB: 2019 update. https://
www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/
en/.)
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Fig. 2. 
Dose escalation. The patient is begun on a low starting dose and the dose is increased every 
few days until the targeted dose is reached. The dose escalation should be completed within 
2 weeks. Some patients will tolerate consolidation of cycloserine to once-daily dosing, 
which can enhance adherence. bid, twice daily; PAS, para-aminosalicylic acid; qam, every 
morning; qhs, at hour of sleep. (From the Curry International TB Center DR TB survival 
guide.17 http://www.currytbcenter.ucsf.edu/products/view/drug-resistant-tuberculosis-
survival-guide-clinicians-3rd-edition.)
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d 
to
 n
eg
at
iv
e 
w
he
n 
2 
co
ns
ec
ut
iv
e 
cu
ltu
re
s, 
ta
ke
n
 a
t l
ea
st 
30
 d
ay
s a
pa
rt,
 a
re
 fo
un
d 
to
 b
e 
ne
ga
tiv
e.
 In
 su
ch
 a
 c
as
e,
 th
e 
sp
ec
im
en
 c
ol
le
ct
io
n 
da
te
 o
f t
he
 fi
rs
t n
eg
at
iv
e 
cu
ltu
re
 is
 u
se
d 
as
 th
e 
da
te
 o
f c
on
v
er
sio
n.
 R
ev
er
sio
n 
(to
 po
sit
ive
) m
ea
ns
 th
at 
cu
ltu
re 
is 
co
n
sid
er
ed
 to
 h
av
e 
re
v
er
te
d 
to
 p
os
iti
v
e 
w
he
n,
 a
fte
r a
n 
in
iti
al
 c
on
v
er
sio
n,
 2
 c
on
se
cu
tiv
e 
cu
ltu
re
s, 
ta
ke
n
 a
t l
ea
st 
30
 d
ay
s a
pa
rt,
 a
re
 fo
un
d 
to
 b
e 
po
sit
iv
e.
 F
o
r 
th
e 
pu
rp
os
e 
of
 d
ef
in
in
g 
tre
at
m
en
t f
ai
le
d,
 re
v
er
sio
n 
is 
co
n
sid
er
ed
 o
nl
y 
w
he
n 
it 
oc
cu
rs
 in
 th
e 
co
nt
in
ua
tio
n 
ph
as
e.
Fr
om
 
th
e 
W
H
O
 D
ef
in
iti
on
s a
nd
 R
ep
or
tin
g 
Fr
am
ew
o
rk
 fo
r T
u
be
rc
ul
os
is,
 2
01
3 
re
v
isi
on
. h
ttp
s:/
/w
w
w.
w
ho
.in
t/t
b/
pu
bl
ic
at
io
ns
/d
ef
in
iti
on
s/e
n/
.
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